London Pharma Holdings Limited acquired 61.2% stake in Alterola Biotech, Inc. from Krono Partners Limited and Michael Frederick Freitag for $0.2 million.
March 29, 2018
Share
London Pharma Holdings Limited acquired 61.2% stake in Alterola Biotech, Inc. (OTCPK:ALTA) from Krono Partners Limited and Michael Frederick Freitag for $0.2 million on March 26, 2018. Under the transaction, buyer purchased 70.33 million shares. On March 26, 2018, Michael Frederick Freitag resigned from the positions as Director and Chief Executive Officer, and Peter E. Maddocks was appointed as Director, Chief Financial Officer and Chief Executive Officer.
London Pharma Holdings Limited completed the acquisition of 61.2% stake in Alterola Biotech, Inc. (OTCPK:ALTA) from Krono Partners Limited and Michael Frederick Freitag on March 26, 2018.
Alterola Biotech, Inc. is a pharmaceutical company. The Company is engaged in the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs); pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs; and European food approval of cannabinoid-based, cannabinoid-like, and non-cannabinoid ingredients and products. The Company has three areas of focus: development of regulated pharmaceuticals (human and animal health) and regulated food products; production of APIs and food-grade ingredients; and formulation, and drug delivery, providing bioavailability, solubility, and stability. It also focuses on developing new medicines from various sources, including botanical, traditional chemical synthesis, and biosynthetic methodologies. Its wholly owned subsidiaries include ABTI Pharma Ltd, Phytotherapeutix Ltd, and Ferven Ltd.
London Pharma Holdings Limited acquired 61.2% stake in Alterola Biotech, Inc. from Krono Partners Limited and Michael Frederick Freitag for $0.2 million.
ALTEROLA BIOTECH, INC. 
